Combination of trastuzumab, capecitabine, oxaliplatin and pembrolizumab showed promising results in patients with HER2-positive metastatic esophagogastric cancer.
J Clin Oncol
In the phase 3 SOLO-1 study, olaparib as frontline maintenance therapy showed significant PFS improvement in ovarian cancer patients carrying BRCA mutation
N Engl J Med
According to the preliminary data of TRITON2 study, rucaparib showed anti-tumor activity in metastatic castration-resistant prostate cancer patients carrying BRCA mutation.
Annals of Oncology
Based on data from a phase II study (B7461001), the FDA approved lorlatinib for the treatment of patients with ALK positive metastatic non–small cell lung cancer (NSCLC) who have progressed on 1 or more ALK tyrosine kinase inhibitors (TKIs)
According to updated phase II findings presented at the 2018 ESMO Congress, infigratinib, a selective pan-FGFR kinase inhibitor, demonstrated a clinical meaningful activity in patients with IHC.
2018 ESMO Congress
This study indicated that RET fusion mutation is one of the mechanisms of drug resistance in EGFR-mutant lung cancer patients after osimertinib treatment. A combination therapy provides a new strategy to overcome the drug resistance
Piotrowska Z, et al., Cancer Discov
The U.S. FDA approves PD-1 inhibitor cemiplimab-rwlc (Libtayo) for the treatment of patients with metastatic or locally advanced cutaneous squamous cell carcinoma (CSCC).
N Engl J Med. &J Clin Oncol.
In the phase I/II TRIDENT-1 study, repotrectinib demonstrates a clinically meaningful response in non-small cell lung cancer (NSCLC) patients carrying ROS1 fusion.
The IASLC 19th World Conference on Lung Cancer
In the phase 3 ALTA-1L study, brigatinib significantly prolongs the progression-free survival (PFS) compared to crizotinib in adult patients with ALK-positive advanced non-small cell lung cancer (NSCLC).
N Engl J Med.
There are limited treatment options in platinum-resistance/refractory ovarian cancer patients. The phase I/II TOPACIO/KEYNOTE-162 study shows that the combination of PARP inhibitor and a PD-1 inhibitor can achieve response in difficult-to treat patients.
J Clin Oncol.